Company
Fennec Pharmaceuticals Inc.
Headquarters: Research Triangle Park, NC, United States
Employees: 10
CEO: Mr. Rostislav Raykov
Market Cap
$165.1 Million
USD as of Jan. 1, 2025
Fennec Pharmaceuticals Inc. Categories
United States Healthcare BiotechnologyUnited States Healthcare United States Biotechnology
Top Competitors by Market Capitalization
Industry: Biotechnology
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $622.07 B |
| Vertex Pharmaceuticals Incorporated | $113.24 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $76.33 B |
| Marinomed Biotech AG | $56.13 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $689.42 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $487.54 B |
| Johnson & Johnson | $353.05 B |
| AbbVie | $301.60 B |
Detailed Description
Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product PEDMARK, a formulation of Sodium Thiosulfate that has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
Top 1-year algo backtest: +327.04%
$10,000 in March 2024 would now be $42,704 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Financials
| Last Financial Reports Date | Dec. 31, 2023 |
| Revenue TTM | $21.3 M |
| EBITDA | $0 |
| Gross Profit TTM | $20.0 M |
| Profit Margin | -75.50% |
| Operating Margin | -18.68% |
| Quarterly Revenue Growth | 534.20% |
Stocks & Indices
Fennec Pharmaceuticals Inc. has the following listings and related stock indices.
Stock: NASDAQ: FENC wb_incandescent
Stock: TSX: FRX wb_incandescent
Stock: FSX: RV41 wb_incandescent